Donald Trump signed a national security memo allowing vetted private companies to conduct offensive cyber-attacks against foreign criminal entities under U.S. government direction, sparking legal and escalation concerns.
US President Donald Trump signs a national security memo enabling vetted private tech firms to partner with federal agencies in executing offensive cyber ops against foreign criminal groups and adversaries, aiming to combat growing cyber threats to American interests.
A new study reveals a significant increase in non-cash donations, particularly private tech company shares, to Donor-Advised Funds (DAFs). This surge is driven by rising IPOs and valuations of AI giants like Anthropic and OpenAI, offering donors tax advantages and immediate deductions.
Modern militaries are developing specialized anti-drone bullets as a close-range defense against unmanned aerial systems. These bullets, designed to fragment or disperse, offer frontline soldiers a practical tool to counter drones that evade larger air defense systems. India's ARDE and private firm SSS Defence are among those developing this technology.
India is making a significant impact at Eurosatory, the world's largest land and air-land defence exhibition in Paris, with 31 entities, including the Ministry of Defence, showcasing advanced technologies. This participation highlights India's growing ambition to be a major global defence supplier, supported by record export figures.
Haryana government asks private companies to implement work-from-home and staggered schedules to reduce traffic, fuel costs, and energy use. This initiative, supported by industry leaders and employees, aims to ease congestion in Gurgaon and aligns with government austerity measures.
Bill Gates expressed concern about the US government's increasing practice of taking equity stakes in private companies, warning it could prioritize ownership over innovation and create policy unpredictability. The government has acquired stakes in companies like Intel, IBM, and various AI and critical minerals firms, raising questions about fairness and long-term strategic planning.
India's defense industry is shifting from state control to private sector leadership, with companies like TASL, L&T, and Bharat Forge shortlisted for the ambitious AMCA fighter jet program. Smaller firms are also expanding, signaling a broader emergence of a private military-industrial complex.
The NHS is spending record sums on private firms to analyze diagnostic scans due to understaffing and a shortage of radiologists. Spending has doubled in five years to £241m, raising concerns about quality and long-term sustainability.
Delhi government advises private firms to implement a two-day work-from-home policy, adjust office hours, and promote carpooling to conserve fuel amid global uncertainties. Essential services are exempt.
The Chinese military must increase the private sector’s role in research to prevent Western sanctions from “strangling” the country’s efforts at defence innovation, a top official of the People’s Liberation Army has urged. Zhang Zhan, political commissar of the National University of Defence Technology (NUDT), said China’s hi-tech industries were facing a “grim and complex” situation as the United States and its allies intensified their campaign to curb access to technology. “[Western] technical...
AngelList has launched USVC, a venture capital fund enabling retail investors to access private companies like OpenAI, Anthropic, and xAI with minimum investments of $500. The fund bypasses accredited investor rules requiring $1M+ net worth, investing capital across emerging fund managers, growth rounds, and secondary equity sales. With a flat 1% management fee and potential quarterly redemption option of up to 5%, USVC has already invested 44% of its capital into seven private firms, with xAI as its largest holding.
Eight mainland China-based companies, including five biotech firms, passed listing hearings on the Hong Kong stock market in April. Metis, founded in 2020 in Hangzhou, uses three proprietary AI platforms to design drug delivery systems. Its revenue surged to 105 million yuan in 2025 from 1.48 million yuan in 2024, while net loss narrowed to 391.8 million yuan. Its leading drug candidate MTS-004 for pseudobulbar affect has completed phase three trials.
Research reveals private firms providing services to the NHS have made £1.6bn in profits over the last two years from contracts worth £12bn, sparking calls for profit caps.
